Millennium Management’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Millennium Management’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-41,517	Closed	-$10K	–	7750
2022 Q2	$10K	Buy	41,517 +2,958	+8%	+$1.02K	﹤0.01%	6687
2022 Q1	$27K	Sell	38,559 -1,542	-4%	-$1.04K	﹤0.01%	6574
2021 Q4	$33K	Buy	40,101 +4,198	+12%	+$4.38K	﹤0.01%	6555
2021 Q3	$49K	Buy	+35,903	New	+$48.7K	﹤0.01%	6580
2020 Q3	–	Sell	-21,974	Closed	-$40K	–	4955
2020 Q2	$40K	Sell	21,974 -14,056	-39%	-$25.6K	﹤0.01%	4065
2020 Q1	$45K	Buy	+36,030	New	+$80.1K	﹤0.01%	3676
2019 Q4	–	Sell	-26,437	Closed	-$158K	–	4767
2019 Q3	$158K	Sell	26,437 -9,367	-26%	-$95.8K	﹤0.01%	3856
2019 Q2	$434K	Sell	35,804 -16,124	-31%	-$216K	﹤0.01%	3329
2019 Q1	$666K	Buy	+51,928	New	+$698K	﹤0.01%	3097

Other funds holding MITO

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Millennium Management's MITO Position: Q3 2022 in Review

Millennium Management sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q3 2022, closing a stake of 41,517 shares — an estimated $10K sold.

Millennium Management first reported a position in MITO in Q1 2019 and held it in 9 quarters. The position peaked at $666K in Q1 2019. 12 funds tracked by Wall St. Rank hold MITO as of Q3 2022.

Millennium Management reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q3 2022 after selling out during the quarter.
Millennium Management sold 41,517 Stealth BioTherapeutics Corp. ADS shares in Q3 2022, an estimated $10K.
Millennium Management first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2019 and held it in 9 quarters.
Millennium Management's Stealth BioTherapeutics Corp. ADS position peaked at $666K in Q1 2019.
12 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.